LISI GROUP - Integrated report 2020

LISI — 2020 INTEGRATED REPORT 73 INTERVIEW JEAN-MARC DURANO CEO, LISI MEDICAL Howdid themedicalmarkets behave in2020? The markets related to orthopedics and scheduled surgery, where LISI MEDICAL operates, experienced very contrasting trends in 2020. The impact of COVID-19 has been staggered over time, as the pandemic progressed. The first effects were felt in China, in Europe and then in the US. While the global market therefore experienced a contrasting decline in activity depending on the strategies deployed in each geography, the stop of surgery reached its peak between March and May. At the height of the lockdown, during which the number of accidents dropped considerably, 80% of orthopedic operations were canceled or postponed. All diseases included the decrease in operating theater activity reached 72% worldwide. This is unprecedented. Altogether, over the whole of 2020, sales of products related to the orthopedics markets fell only by around 20%. How has LISI MEDICAL’s business been impacted? The implant-related activity was more strongly affected insofar as it was directly impacted by the general decline in surgical activity. Minimally invasive surgery, on the other hand, was less affected because we were in the manufacturing phase for the launch of new products at our customers and deliveries were generally maintained. LISI MEDICAL is indeed a world-class manufacturer whose customers – the main €116 m 2020 SALES 9% AS A % OF GROUP SALES 744 EMPLOYEES AROUND THE WORLD Post-crisis, LISIMEDICALwill be in a position to gainnewmarket share in certain segmentswherewewish to consolidate our positions.